Clinical Trial Update: Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating BAY1817080 at three doses vs placebo and elagolix in endometriosis; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometriosis

Drugs mentioned

• BAY1817080
• Elagolix (elagolix)

Snippet

Sponsor: Bayer | Conditions: Endometriosis | Phase 2 | Status: TERMINATED | Results posted: 2023-05-31